University of Florida Research Foundation Inc

University of Pittsburgh

Other

The University of Melbourne

Corthera Inc.

University of Medicine and Dentistry of New Jersey

Kirk P. Conrad

Sanjeev G. Shroff

Kirk P Conrad

Sanjeev G Shroff

Elaine Unemori

Martyn A Lewis

Dennis Stewart

Xinfan Huang

Mark S Segal

Laura Parry

Arundhathi Jeyabalan

Carol A Tozzi

Martyn Lewis

Elaine N Unemori

The subject invention provides methods for recruitment of bone marrow-derived cells, including bone marrow-derived endothelial cells (BMDEC), and increasing their function by administration of relaxin. The methods of the invention can be used in, for example, treating conditions amenable to treatment by recruitment of bone marrow-derived cells, such as BMDEC and bone marrow-derived angio-osteogcnic progenitor cell.

Materials and methods for modulating activity of bone marrow derived cells

The subject invention relates to methods for improving a subject's vasculature to normalize maternal hemodynamics, particularly in subjects attempting to conceive via assisted reproductive technologies, and comprises increasing relaxin levels in a subject or increasing any one or more of: relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, or relaxin receptor activity.

Use of relaxin to restore maternal physiology in pregnancies conceived by assisted reproductive technologies

The subject application relates to methods for treating a placental syndrome, wherein relaxin is administered during the late secretory/luteal (LS) phase of the menstrual cycle in women who have a propensity for developing the placental syndrome. In certain embodiments, administration of relaxin continues beyond the LS phase and into pregnancy.

Use of relaxin to treat placental syndromes

The present disclosure relates to methods of modulating aquaporin channels. Particularly, the disclosure provides methods of modulating aquaporin channels in a tissue of a mammal by administering relaxin.

Administration of relaxin to treat nephrogenic diseases of water imbalance involving aquaporin-4

The present invention provides methods for increasing arterial compliance. The methods generally involve administering to an individual in need thereof an effective amount of relaxin. The present invention further provides methods of increasing arterial compliance in individuals who have Type 1 or Type 2 diabetes. The present invention further provides methods of increasing arterial compliance in perimenopausal, menopausal, and post-menopausal women. The present invention further provides methods of increasing arterial compliance in individuals who have or who are at risk of developing age-associated arterial stiffness.

Use of relaxin to increase arterial compliance

The present disclosure relates to methods for detecting an increased risk of preeclampsia, determining the presence of preeclampsia, reducing the likelihood that preeclampsia will develop and treating preeclampsia. It also provides methods of measuring relaxin levels in a biological sample of a pregnant woman.

Prediction and prevention of preeclampsia

The invention related to methods of treating disease related to vasoconstriction that is a major factor in hypertensive vascular diseases and vasodilation, generally comprising administering to an individual an effective amount of a pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females, and is useful in treating a wide variety of diseases relating to vasoconstriction.

Growing community of inventors

Gainesville, FL, United States of America

Kirk P Conrad